The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM).
K. B. Kim
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Plexxikon; Roche
K. T. Flaherty
Consultant or Advisory Role - Roche/Genentech
P. B. Chapman
Consultant or Advisory Role - Roche
Research Funding - Roche
J. A. Sosman
Consultant or Advisory Role - Roche
Honoraria - Roche
A. Ribas
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
G. A. McArthur
Consultant or Advisory Role - Roche (U)
R. K. Amaravadi
No relevant relationships to disclose
R. J. Lee
Employment or Leadership Position - Roche
K. B. Nolop
Employment or Leadership Position - Plexxikon
Stock Ownership - Plexxikon
I. Puzanov
Consultant or Advisory Role - Roche